Back to Newsroom

Catalyst Pharmaceuticals Announces a Clinical Trial for Pediatric Patients With Congenital Myasthenic Syndromes

CORAL GABLES, Fla., Oct. 06, 2015 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced a clinical trial with Firdapse® (amifampridine phosphate)  in pediatric patients with congenital myasthenic syndromes (CMS). Firdapse has received Breakthrough Therapy Designation from the FDA for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS), as well as orphan drug designations for LEMS and CMS. – See more at: http://globenewswire.com/news-release/2015/10/06/773786/0/en/Catalyst-Pharmaceuticals-Announces-a-Clinical-Trial-for-Pediatric-Patients-With-Congenital-Myasthenic-Syndromes.html#sthash.cVSYZoTV.dpuf

Click here to read more